Precision-Guided Dosing

PredictrPK UST maintenance is a laboratory-developed test that was developed, and analytically and clinically validated by Prometheus Laboratories Inc. under federal Clinical Laboratory Improvement Amendments (CLIA) guidelines for adult IBD patients undergoing maintenance ustekinumab therapy, and is performed exclusively in our high complexity CLIA-certified and College of American Pathologists-accredited clinical laboratory. As laboratory a developed test, it has not been cleared or approved by the US FDA. This test is not yet available for patients in NY-State. This test may be covered by one or more US pending or issued patents – see prometheuslabs.com/patents. This material is provided for general information purposes only as an educational service for healthcare physicians and their patients. It is not intended as a substitute for medical advice and/or consultation with a physician.